These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 15772958)

  • 1. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
    Bendell JC; Eder JP; Clark JW; Fidias P; Lynch TJ; Seiden MV; Ryan DP
    Cancer; 2005 May; 103(9):1925-31. PubMed ID: 15772958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
    Flaherty KT; Stevenson JP; Gallagher M; Giantonio B; Algazy KM; Sun W; Haller DG; O'Dwyer PJ
    Cancer; 2003 Apr; 97(8):1985-90. PubMed ID: 12673728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tezacitabine Hoechst Marion Roussel.
    Seley KL
    Curr Opin Investig Drugs; 2000 Sep; 1(1):135-40. PubMed ID: 11249589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
    Tsujie M; Nakamori S; Tanaka E; Nagano H; Umeshita K; Dono K; Sakon M; Inoue T; Inoue T; Monden M
    Jpn J Clin Oncol; 2006 Aug; 36(8):504-10. PubMed ID: 16855011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
    Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
    Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
    Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
    Cunningham C; Nemunaitis J
    Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.
    Burtness B; Belker M; Stoltz M; Peccerillo KM; Lamb LA; Chmael SE; McKeon A; Clark MB; Winship J; Marsh JC; Pizzorno G; DeVita VT
    Cancer J; 2000; 6(5):309-15. PubMed ID: 11079170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.